sanguisorba
radix
sr
well
known
herbal
medicin
name
ziyu
korea
dri
root
sanguisorba
officinali
l
rosaceas
investig
underli
mechan
inhibit
atop
dermat
ad
ethanol
extract
sr
esr
use
dncb
induc
ad
mice
model
oral
administr
esr
significantli
suppress
dncbinduc
adlik
symptom
scratch
behavior
ear
thick
epiderm
thick
ige
level
investig
effect
esr
treatment
degranul
igeagactiv
mous
bone
marrowderiv
mast
cell
bmmc
measur
releas
hexosaminidas
hex
degranul
marker
esr
decreas
infiltr
eosinophil
mast
cell
ad
skin
lesion
furthermor
esr
significantli
inhibit
degranul
igeagactiv
bmmc
demonstr
esr
decreas
ad
symptom
mice
inhibit
degranul
igeagactiv
mast
cell
studi
suggest
esr
may
serv
potenti
therapeut
candid
treatment
ad
symptom
atop
dermat
ad
chronic
inflammatori
skin
diseas
ad
caus
epiderm
thick
cutan
hypersensit
associ
increas
serum
immunoglobulin
e
ige
level
infiltr
inflammatori
cell
type
includ
mast
cell
eosinophil
ad
complex
interact
innat
adapt
immun
respons
base
individu
genet
environment
pharmacolog
psycholog
condit
ige
secret
import
characterist
ad
elev
level
relat
diseas
sever
ad
patient
previou
studi
report
high
serum
ige
level
induc
activ
mast
cell
caus
allerg
reaction
mast
cell
aggreg
highaffin
ige
receptor
fc
ri
surfac
import
proinflammatoryallerg
respons
mast
cell
believ
play
import
role
induct
ad
associ
mast
cell
activ
ad
suggest
increas
mast
cell
count
activ
ad
lesion
addit
mast
cell
produc
inflammatori
mediat
prostaglandin
pgd
induc
eosinophil
chemotaxi
inflammatori
site
skin
ad
patient
sanguisorba
radix
sr
well
known
herbal
medicin
name
ziyu
korea
dri
root
sanguisorba
officinali
l
rosaceas
sr
use
tradit
herbal
medicin
treat
diarrhea
chronic
intestin
infect
duoden
ulcer
intern
hemorrhag
burn
sr
includ
saponin
glycosid
ellagitannin
ie
pomol
acid
sanguisorb
acid
dilacton
ziyuglycosid
sr
activ
compon
demonstr
biolog
activ
vivo
vitro
sr
inhibit
renal
dysfunct
induc
lipopolysaccharid
lp
endotoxin
vivo
suppress
serum
nitritenitr
level
activ
induc
nitric
oxid
synthas
ino
addit
sr
report
antioxid
stress
antiag
activ
via
suppress
nitric
oxid
product
activ
ino
sr
block
h
induc
ro
gener
vitro
mcaoinduc
ischem
brain
damag
vivo
addit
report
properti
sr
includ
anticanc
antiasthma
anticoronaviru
antiwrinkl
activ
mani
research
report
antiinflammatori
activ
sr
nonetheless
antiatop
dermat
effect
sr
report
recent
studi
report
inhibitori
effect
sr
contact
dermat
report
antiinflammatori
mechan
esr
human
keratinocyt
suppress
express
tnfifn
stimul
chemokin
proinflammatori
molecul
via
blockad
nfb
erk
activ
howev
biolog
pharmacolog
action
sr
fulli
understood
atop
dermat
studi
examin
effect
esr
dncb
induc
ad
mous
skin
lesion
mous
bone
marrowderiv
mast
cell
bmmc
determin
therapeut
potenti
treatment
ad
yeongcheon
orient
herbal
market
yeongcheon
korea
sampl
deposit
herbal
bank
km
applic
center
korea
institut
orient
medicin
kiom
daejeon
republ
korea
prepar
esr
dri
sr
piec
g
extract
use
ml
ethanol
c
shake
incub
h
obtain
g
give
us
yield
male
balbc
mice
week
old
purchas
samtako
bio
korea
osan
korea
mice
observ
everi
day
one
week
quarantin
acclim
mice
divid
six
group
per
group
neg
control
vehicl
dncb
vehicl
control
dncb
mgkg
esr
dncb
mgkg
esr
dncb
mgkg
esr
mgkg
dexamethason
dexa
group
maintain
standard
condit
temperatur
c
humid
h
light
pm
lx
ventil
time
per
hour
diet
teklad
global
diet
harlan
laboratori
inc
usa
studi
conduct
accord
guidelin
list
pharmaceut
affair
act
korea
food
drug
associ
kfda
approv
institut
anim
care
use
committe
korea
conform
laboratori
treatment
week
acclim
dncb
appli
dorsal
skin
ear
balbc
mice
induc
adlik
symptom
skin
lesion
one
day
complet
dorsal
hair
remov
l
dncb
dissolv
aceton
oliv
oil
mixtur
volvol
appli
dorsal
skin
l
appli
ear
day
five
day
dorsal
hair
remov
dncb
dissolv
aceton
oliv
oil
mixtur
volvol
appli
challeng
dorsal
skin
l
ear
l
two
time
week
week
similarli
dncb
solut
appli
one
day
prior
sacrific
esr
dissolv
salin
mlkg
bodi
weight
oral
administ
gavag
mgkg
use
dexamethason
sigmaaldrich
st
loui
mo
usa
mgkg
three
time
week
week
day
experiment
scheme
summar
figur
scratch
behavior
measur
place
mous
cage
week
min
observ
record
behavior
mous
ear
thick
measur
record
micromet
mitutoyo
kawasaki
japan
minim
variat
singl
investig
perform
measur
end
studi
period
dorsal
skin
lesion
mous
remov
fix
neutralbuff
formalin
embed
paraffin
thick
section
stain
hematoxylin
eosin
h
e
toluidin
blue
detect
epiderm
thick
inflammatori
cell
ie
eosinophil
mast
cell
respect
histopatholog
evalu
skin
section
occur
blind
fashion
sampl
observ
use
invert
microscop
data
repres
five
observ
nikon
eclips
ti
nikon
tokyo
japan
end
studi
period
mice
sacrif
whole
blood
collect
blood
sampl
centrifug
min
c
serum
obtain
whole
blood
store
c
use
serum
ige
level
measur
use
enzymelink
immunosorb
assay
elisa
kit
accord
manufactur
instruct
biolegend
san
diego
ca
usa
inhibitori
effect
esr
determin
base
absorb
nm
measur
use
multilabel
micropl
reader
spectramax
molecular
devic
silicon
valley
ca
usa
bmmc
isol
male
balbc
mice
cultur
week
media
contain
mm
lglutamin
mm
nonessenti
amino
acid
antibiot
fetal
bovin
serum
fb
pokewe
mitogenstimul
spleen
condit
medium
pwmscm
sourc
week
cell
verifi
bmmc
accord
previous
describ
procedur
cell
cytotox
analyz
use
cell
count
kit
cck
dojindo
molecular
technolog
inc
kumamoto
japan
bmmc
cellswel
seed
plate
h
esr
ad
concentr
gml
plate
incub
h
c
co
incub
cck
solut
ad
well
cell
incub
h
optic
densiti
measur
nm
use
harvest
supernat
accord
previous
describ
procedur
percentag
hex
releas
supernat
calcul
use
follow
formula
supernat
supernat
pellet
analysi
data
analyz
use
graphpad
prism
softwar
ver
graphpad
softwar
san
diego
ca
usa
result
express
mean
standard
error
mean
sem
evalu
use
student
ttest
analysi
varianc
anova
valu
less
consid
statist
signific
investig
therapeut
effect
esr
ad
mous
lesion
administ
esr
follow
induct
ad
mous
skin
lesion
use
dncb
topic
applic
dncbinduc
crust
epiderm
thick
red
dryness
skin
shown
figur
b
howev
skin
condit
significantli
improv
esradminist
group
compar
control
group
scratch
behavior
control
group
rapidli
increas
becam
significantli
differ
observ
vehicl
group
day
dncb
applic
ad
mice
treat
mgkg
esr
scratch
inhibit
strongli
compar
vehicl
group
figur
addit
esr
significantli
reduc
dncbinduc
ear
thick
dosedepend
manner
result
suggest
esr
therapeut
effect
reduc
ad
symptom
mice
figur
b
level
ad
mice
elev
serum
ige
level
mast
cell
infiltr
major
characterist
ad
relat
diseas
sever
assess
effect
esr
mast
cell
infiltr
stain
slice
cross
section
skin
lesion
toluidin
blue
shown
figur
found
increas
mast
cell
infiltr
figur
b
ige
level
dncbtreat
mice
compar
vehicl
group
figur
c
howev
esr
significantli
decreas
level
ige
elev
dncb
induct
inhibit
mast
cell
infiltr
dosedepend
manner
figur
b
c
degranul
degranul
mast
cell
correl
ad
sever
recruit
immun
cell
inflammatori
site
ad
patient
investig
effect
esr
treatment
degranul
igeagactiv
bmmc
measur
releas
hex
presenc
absenc
esr
shown
figur
b
esr
potent
reduc
hex
releas
dosedepend
manner
check
cytotox
esr
bmmc
cell
incub
differ
esr
concentr
gml
h
subject
assay
esr
gml
signific
cytotox
effect
bmmc
h
figur
ad
inflammatori
diseas
character
increas
cell
associ
respons
includ
monocyt
macrophag
eosinophil
mast
cell
pathogenesi
ad
primarili
driven
immun
respons
increas
ige
product
prolifer
migrat
local
activ
eosinophil
common
ad
eosinophil
act
immunoregulatori
factor
secret
varieti
cytokin
chemokin
attract
eosinophil
site
inflamm
furthermor
eosinophil
promot
switch
acut
chronic
respons
ad
esr
treatment
reduc
eosinophil
accumul
ad
mous
skin
lesion
figur
c
high
level
serum
ige
repres
anoth
characterist
ad
thu
like
target
ige
may
impact
ad
diseas
outcom
specif
ige
bind
mast
cell
affect
develop
sever
ad
mast
cell
play
key
role
allerg
reaction
via
product
secret
proinflammatori
mediat
histamin
chemokin
cytokin
growth
factor
surfac
mast
cell
cell
produc
ige
bind
fc
ri
mast
cell
surfac
fc
rimedi
mast
cell
activ
trigger
antigen
ige
crosslink
lead
degranul
express
proinflammatori
mediat
fc
riactiv
mast
cell
induc
ige
elev
increas
mast
cell
major
ad
patient
therefor
mast
cell
hypothes
contribut
pathogenesi
ad
find
show
esr
treatment
suppress
serum
ige
level
mast
cell
infiltr
dncbinduc
ad
mous
model
hex
degranul
marker
releas
along
proinflammatori
mediat
mast
cell
activ
therefor
examin
degranul
measur
hex
releas
antigen
igeactiv
bmmc
confirm
esr
treatment
inhibit
hex
releas
dosedepend
manner
activ
compon
sr
includ
phenol
compound
includ
tannin
flavonoid
saponin
glycosid
ellagitannin
ie
pomol
acid
sanguisorb
acid
dilacton
ziyuglycosid
ziyuglycosid
ziyuglycosid
ii
major
effect
ingredi
triterpenoid
saponin
extract
sanguisorba
officinali
l
mani
studi
focus
pharmacolog
activ
addit
ziyuglycosid
major
marker
sr
confirm
origin
medicin
plant
korean
pharmacopoeia
thu
use
ziyuglycosid
phytochem
marker
sr
experi
data
shown
studi
investig
therapeut
effect
esr
treatment
ad
use
dncbinduc
ad
mous
model
bmmc
esr
significantli
improv
scratch
behavior
ear
thick
epiderm
thick
serum
ige
level
dncbinduc
ad
mice
observ
reduct
infiltr
eosinophil
mast
cell
ad
skin
lesion
follow
esr
treatment
addit
esr
significantli
inhibit
degranul
igeagactiv
bmmc
therapeut
effect
esr
treatment
ad
support
benefici
effect
antiig
therapi
number
clinic
studi
conclus
result
demonstr
esr
decreas
ad
symptom
mice
inhibit
degranul
igeagactiv
mast
cell
studi
suggest
esr
may
serv
potenti
therapeut
candid
treatment
ad
ethanol
extract
sanguisorba
radix
ad
atop
dermat
dncb
h
e
hematoxylin
eosin
fc
ri
highaffin
immunoglobulin
e
receptor
bmmc
mous
bone
marrowderiv
mast
cell
hex
hexosaminidas
